Differential diagnosis and follow-up of cystic neoplasms of the pancreas: advanced radiologic imaging and cyst fluid analysis

Differential diagnosis and follow-up of cystic neoplasms of the pancreas: advanced radiologic imaging and cyst fluid analysis - Pancreatic cysts study

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

NL-OMON

Registry ID

NL-OMON30334

Enrollment

150

Registered

2006-09-22

Start date

2006-10-01

Completion date

Unknown

Last updated

2024-05-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

cystic tumors of the pancreas neoplastic cysts

Interventions

None listed

Eligibility

Age

18 Years to 99 Years

Inclusion criteria

Inclusion criteria: Cystic lesion on cross-sectional imaging (percutaneous ultrasound and/or CT scan and/or MR scan) Suspicion of a pancreatic neoplasm

Exclusion criteria

Exclusion criteria: Acute phase of an acute pancreatitis PT-INR>1.5, PTT>50, trombocytes

Design outcomes

Primary

Measure	Time frame
The primary aims are to identify new means to improve the differential diagnosis of pancreatic cystic lesions to guide patient management and to assess the biological behaviour of the pancreatic cystic lesions.	—

Secondary

Measure	Time frame
To describe a large single-centre experience with pancreatic cystic lesions, including presenting signs and symptoms and methods of diagnosis. To assess the development and natural behaviour of pancreatic cysts according to a predefined follow-up scheme/ regimen. To identify new biomarkers of pancreatic cystic neoplasms using proteomics technology and assess their feasibility and reliability compared to well-known tumor markers and enzymes for pathological diagnosis in patients with a pancreatic cystic lesion. To make recommendations for the accurate diagnosis and optimal treatment of patients with all types of pancreatic cystic lesions.	—

Measure

Time frame

To describe a large single-centre experience with pancreatic cystic lesions, including presenting signs and symptoms and methods of diagnosis. To assess the development and natural behaviour of pancreatic cysts according to a predefined follow-up scheme/ regimen. To identify new biomarkers of pancreatic cystic neoplasms using proteomics technology and assess their feasibility and reliability compared to well-known tumor markers and enzymes for pathological diagnosis in patients with a pancreatic cystic lesion. To make recommendations for the accurate diagnosis and optimal treatment of patients with all types of pancreatic cystic lesions.

—

Countries

Netherlands

Outcome results